Working Paper Review Version 1 This version is not peer-reviewed

Hodgkin Lymphoma In People Living With HIV

Version 1 : Received: 31 May 2021 / Approved: 2 June 2021 / Online: 2 June 2021 (11:53:29 CEST)

How to cite: Navarro, J.T.; Moltó, J.; Tapia, G.; Ribera, J.M. Hodgkin Lymphoma In People Living With HIV. Preprints 2021, 2021060071 Navarro, J.T.; Moltó, J.; Tapia, G.; Ribera, J.M. Hodgkin Lymphoma In People Living With HIV. Preprints 2021, 2021060071

Abstract

Despite widespread use of combined antiretroviral therapy (ART) and increased life expectancy in people living with HIV (PLWH), HIV-related lymphomas (HRL) remain a leading cause of cancer morbidity and mortality for PLWH, even in patients optimally treated with ART. While incidence of aggressive forms of non-Hodgkin lymphoma decreased after ART advent, incidence of Hodgkin lymphoma (HL) has increased among PLWH in recent decades. The coinfection of Epstein Barr virus plays a crucial role in the pathogenesis of HL in the HIV setting. Currently, PLWH with HRL, including HL, are treated similarly to HIV-negative patients and, importantly, the prognosis of HL in PLWH is approaching to that of the general population. In this regard, effective chemotherapy is strongly recommended since it has been shown to improve survival rates in all lymphoma subtypes, including HL. As a consequence, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential drug-drug interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PLWH with HL. In this article the authors review and update the epidemiological, clinical and biological aspects of HL presenting in PLWH with special emphasis in the improvement on prognosis and the factors that have contributed to it.

Keywords

Hodgkin lymphoma, HIV; antiretroviral therapy; prognosis; etiopathogenesis

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.